Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (62)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (235)
  2. Center for Hematologic Malignancies (235)
  3. Department of Medicine (235)
  4. Hematologic Malignancies, Division of (235)
  5. Lymphoma (47)
  6. GME, Medicine (32)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (3)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (235)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiation therapy for patients with diffuse large B cell Richter's syndrome of CLL
    Meeting Abstract

    Sacchi De Camargo Correia, G.; Imber, B. S.; Hajj, C.; Thompson, M. C.; Mato, A. R.; Yahalom, J.; Roeker, L. E.
    Blood (2021)

    Fulltext@MSK | Save
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Journal Article

    Wang, X. V.; Hanson, C. A.; Tschumper, R. C.; Lesnick, C. E.; Braggio, E.; Paietta, E. M.; O'Brien, S.; Barrientos, J. C.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902)
    Meeting Abstract

    Stephens, D. M.; Moseley, A.; Hill, B. T.; Pagel, J. M.; Shadman, M.; Fisch, M. J.; Danilov, A. V.; Ng, D.; Mato, A. R.; Brander, D. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting
    Meeting Abstract

    Mato, A. R.; Tang, B.; Azmi, S.; Yang, K.; Wallis, N.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies
    Journal Article

    Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies
    Research Letter

    Roeker, L. E.; Eyre, T. A.; Thompson, M. C.; Lamanna, N.; Coltoff, A. R.; Davids, M. S.; Baker, P. O.; Leslie, L.; Rogers, K. A.; Allan, J. N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Phase 1/2 BRUIN study results
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fahkri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Insights from the informCLL registry: Real-world application of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Meeting Abstract

    Ghosh, N.; Brander, D.; Mato, A. R.; Sharman, J. P.; Gutierrez, M.; Naganuma, M.; Upasani, S.; Alagappan, D.; Huang, Q.; Young, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Roeker, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save